NovoCure Limited (NVCR) Stock Rating Upgraded by Zacks Investment Research

Ausiliatrice Cristiano
Luglio 14, 2017

The current market capitalization of Novocure Ltd Ord Sh (NASDAQ:NVCR) stands at 1.6 Billion. The company has an average rating of "Buy" and a consensus target price of $17.00. Over the past month the firm's stock is -10.03%, -43.28% for the last quarter, -47.83% for the past six-months and -41.67% for the a year ago. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

On Tuesday, July 11th, Asaf Danziger sold 7,383 shares of NovoCure Limited stock.

NovoCure Limited (NASDAQ:NVCR) marched up 236.13% compared to a 52-week low price of $5.95. However, most financial instruments are traded after hours which mean that the closing price of a stock might not match the after-hours price. The shares were sold at an average price of $18.14, for a total transaction of $2,813,296.32. NVCR's SI was 7.01M shares in July as released by FINRA. The shares were sold at an average price of $18.14, for a total value of $2,904,903.32. A total volume of 0.84 million shares were traded versus to average volume of 0.81 million shares.

The stock has Return on Assets (ROA) of -42.1 percent. The shares were sold at an average price of $15.13, for a total transaction of $2,732,493.13.

How Active Are NovoCure Limited (NASDAQ:NVCR) Shares? On Monday, May 1 ZIESER JOHN S sold $100,631 worth of Meredith Corporation (NYSE:MDP) or 1,742 shares.

NovoCure Limited (NASDAQ:NVCR) opened at 19.80 on Friday. Novocure has a 52-week low of $5.95 and a 52-week high of $17.90. That value represents a market adjusting for revenues that have been growing by 167.22 % on a quarterly year/year basis as of the company's last quarterly report. The firm's 50 day moving average price is $14.10 and its 200 day moving average price is $9.87.

Many analysts have provided their estimated foresights on NovoCure Limited Earnings, with 5 analysts believing the company would generate an Average Estimate of $-0.22. The medical equipment provider reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.04. The company generated a return on equity (ROE) of -74.30%. As of the last earnings report the EPS was $-1.33 and is projected to be $-0.80 for the current year with 88,149,000 shares now outstanding.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another domain, it was stolen and republished in violation of USA and global trademark & copyright law. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/07/14/novocure-limited-nasdaqnvcr-ceo-asaf-danziger-sells-180601-shares.html. Bank Of Montreal /can/ augmented its investment by buying 6,369 shares an increase of 1,819.7% from 03/31/2017 to 06/30/2017. Fox Run Management L.L.C. acquired a new stake in shares of NovoCure Limited during the second quarter valued at approximately $225,000. Vanguard Group Inc. boosted its position in NovoCure Limited by 12.0% in the first quarter. Macquarie Group Ltd. now owns 98,087 shares of the medical equipment provider's stock worth $770,000 after buying an additional 15,218 shares in the last quarter. Geode Capital Management LLC raised its position in shares of NovoCure Limited by 14.6% in the first quarter. Geode Capital Management LLC now owns 128,632 shares of the medical equipment provider's stock worth $1,041,000 after buying an additional 16,411 shares in the last quarter. Finally, Wedbush Securities Inc. bought a new stake in shares of Novocure during the first quarter valued at about $381,000. Teachers Advisors LLC now owns 95,674 shares of the medical equipment provider's stock worth $751,000 after buying an additional 16,741 shares in the last quarter. Institutional investors and hedge funds own 24.19% of the company's stock.

Several analysts have recently commented on NVCR shares. J P Morgan Chase & Co restated a "buy" rating and issued a $14.00 target price on shares of NovoCure Limited in a research note on Monday, May 1st.

04/18/2017 - NovoCure Limited had its "buy" rating reiterated by analysts at Aegis Capital. Finally, Deutsche Bank AG raised their price objective on NovoCure Limited from $10.00 to $11.00 and gave the company a "hold" rating in a report on Friday, April 28th. The stock of Novocure Ltd (NASDAQ:NVCR) earned "Outperform" rating by Wedbush on Tuesday, October 27.

Why NovoCure Limited (NVCR) stock is considered to be Overbought?

NovoCure Limited (NVCR) closed business day at $20.00 with 10.50%.

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE